JP2018501247A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018501247A5 JP2018501247A5 JP2017533220A JP2017533220A JP2018501247A5 JP 2018501247 A5 JP2018501247 A5 JP 2018501247A5 JP 2017533220 A JP2017533220 A JP 2017533220A JP 2017533220 A JP2017533220 A JP 2017533220A JP 2018501247 A5 JP2018501247 A5 JP 2018501247A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- pharmaceutical composition
- composition according
- antibody
- therapeutically effective
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims description 33
- 239000000203 mixture Substances 0.000 claims description 31
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 30
- 206010028980 Neoplasm Diseases 0.000 claims description 17
- 201000011510 cancer Diseases 0.000 claims description 15
- 108091008036 Immune checkpoint proteins Proteins 0.000 claims description 14
- 102000037982 Immune checkpoint proteins Human genes 0.000 claims description 14
- 210000000987 immune system Anatomy 0.000 claims description 11
- 230000037396 body weight Effects 0.000 claims description 10
- 230000003213 activating effect Effects 0.000 claims description 7
- 229940045513 CTLA4 antagonist Drugs 0.000 claims description 6
- 206010061328 Ovarian epithelial cancer Diseases 0.000 claims description 6
- 230000028993 immune response Effects 0.000 claims description 6
- 208000036832 Adenocarcinoma of ovary Diseases 0.000 claims description 3
- 206010005003 Bladder cancer Diseases 0.000 claims description 3
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 3
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- 206010009944 Colon cancer Diseases 0.000 claims description 3
- 206010052360 Colorectal adenocarcinoma Diseases 0.000 claims description 3
- 108090000695 Cytokines Proteins 0.000 claims description 3
- 102000004127 Cytokines Human genes 0.000 claims description 3
- 206010062904 Hormone-refractory prostate cancer Diseases 0.000 claims description 3
- -1 IL-12p70 Proteins 0.000 claims description 3
- 108010002350 Interleukin-2 Proteins 0.000 claims description 3
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 3
- 208000030070 Malignant epithelial tumor of ovary Diseases 0.000 claims description 3
- 206010027406 Mesothelioma Diseases 0.000 claims description 3
- 208000007571 Ovarian Epithelial Carcinoma Diseases 0.000 claims description 3
- 206010033128 Ovarian cancer Diseases 0.000 claims description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 3
- 206010060862 Prostate cancer Diseases 0.000 claims description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 3
- 206010038389 Renal cancer Diseases 0.000 claims description 3
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 3
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 3
- 241000700605 Viruses Species 0.000 claims description 3
- 230000001093 anti-cancer Effects 0.000 claims description 3
- 208000029742 colonic neoplasm Diseases 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 210000003162 effector t lymphocyte Anatomy 0.000 claims description 3
- 208000005017 glioblastoma Diseases 0.000 claims description 3
- 201000010536 head and neck cancer Diseases 0.000 claims description 3
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 3
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 3
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 3
- 208000015181 infectious disease Diseases 0.000 claims description 3
- 201000010982 kidney cancer Diseases 0.000 claims description 3
- 201000007270 liver cancer Diseases 0.000 claims description 3
- 208000014018 liver neoplasm Diseases 0.000 claims description 3
- 201000005202 lung cancer Diseases 0.000 claims description 3
- 208000020816 lung neoplasm Diseases 0.000 claims description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 3
- 201000001441 melanoma Diseases 0.000 claims description 3
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 3
- 208000013371 ovarian adenocarcinoma Diseases 0.000 claims description 3
- 201000006588 ovary adenocarcinoma Diseases 0.000 claims description 3
- 201000002528 pancreatic cancer Diseases 0.000 claims description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 3
- 244000045947 parasite Species 0.000 claims description 3
- 230000037361 pathway Effects 0.000 claims description 3
- 102000004169 proteins and genes Human genes 0.000 claims description 3
- 108090000623 proteins and genes Proteins 0.000 claims description 3
- 210000003289 regulatory T cell Anatomy 0.000 claims description 3
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 3
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 3
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 3
- 102100023990 60S ribosomal protein L17 Human genes 0.000 claims description 2
- 108010074708 B7-H1 Antigen Proteins 0.000 claims description 2
- 102000008096 B7-H1 Antigen Human genes 0.000 claims description 2
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims description 2
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims description 2
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 claims description 2
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 claims description 2
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 claims description 2
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 230000000694 effects Effects 0.000 claims 1
- 238000002649 immunization Methods 0.000 claims 1
- 230000003053 immunization Effects 0.000 claims 1
- 210000003292 kidney cell Anatomy 0.000 claims 1
- 238000000034 method Methods 0.000 description 10
- 230000001225 therapeutic effect Effects 0.000 description 3
- 208000006265 Renal cell carcinoma Diseases 0.000 description 2
- 208000000453 Skin Neoplasms Diseases 0.000 description 2
- 201000000849 skin cancer Diseases 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462094944P | 2014-12-19 | 2014-12-19 | |
| US62/094,944 | 2014-12-19 | ||
| PCT/US2015/066400 WO2016100679A1 (en) | 2014-12-19 | 2015-12-17 | Immunotherapy treatments and compositions |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018501247A JP2018501247A (ja) | 2018-01-18 |
| JP2018501247A5 true JP2018501247A5 (enExample) | 2019-01-10 |
| JP6649953B2 JP6649953B2 (ja) | 2020-02-19 |
Family
ID=56127600
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017533220A Expired - Fee Related JP6649953B2 (ja) | 2014-12-19 | 2015-12-17 | 免疫療法による治療および組成物 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US10624965B2 (enExample) |
| EP (1) | EP3233104B1 (enExample) |
| JP (1) | JP6649953B2 (enExample) |
| AU (1) | AU2015364559B2 (enExample) |
| CA (1) | CA2971471C (enExample) |
| DK (1) | DK3233104T3 (enExample) |
| ES (1) | ES2781673T3 (enExample) |
| WO (1) | WO2016100679A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018039132A1 (en) * | 2016-08-24 | 2018-03-01 | Wisconsin Alumni Research Foundation | Methods and compositions for the treatment of cancer |
| AU2019205279A1 (en) * | 2018-01-08 | 2020-07-30 | Susavion Biosciences, Inc. | Compositions and methods of treating cancer with glycomimetic peptides |
| CA3185526A1 (en) * | 2020-07-28 | 2022-02-03 | Laura L. Eggink | Method of treatment of neutrophil-driven inflammatory pathologies |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005087793A2 (en) * | 2004-02-05 | 2005-09-22 | The Arizona Board Of Regents, A Body Corporate Acting On Behalf Of Arizona State University | Immunostimulatory compositions and uses thereof |
| US7838497B2 (en) * | 2006-12-13 | 2010-11-23 | Susavion Biosciences, Inc. | Pro-angiogenic peptides |
| EP2262837A4 (en) * | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
| CA3017298C (en) * | 2009-05-15 | 2021-09-28 | Irx Therapeutics, Inc. | Compositions comprising primary cell-derived biologics for enhancing immune responses in patients |
| GB0920258D0 (en) * | 2009-11-19 | 2010-01-06 | Alligator Bioscience Ab | New medical agents and use thereof |
| WO2013096829A2 (en) | 2011-12-22 | 2013-06-27 | Arizona Biomedical Research Commission | Activation of cellular assault processes in the treatment of glioblastoma multiforme |
| US9856320B2 (en) * | 2012-05-15 | 2018-01-02 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting PD-1/PD-L1 signaling |
| US9682143B2 (en) | 2012-08-14 | 2017-06-20 | Ibc Pharmaceuticals, Inc. | Combination therapy for inducing immune response to disease |
| EP2892558B1 (en) * | 2012-09-07 | 2019-04-10 | The Trustees Of Dartmouth College | Vista modulators for diagnosis and treatment of cancer |
-
2015
- 2015-12-17 CA CA2971471A patent/CA2971471C/en active Active
- 2015-12-17 AU AU2015364559A patent/AU2015364559B2/en not_active Ceased
- 2015-12-17 WO PCT/US2015/066400 patent/WO2016100679A1/en not_active Ceased
- 2015-12-17 US US15/537,731 patent/US10624965B2/en active Active
- 2015-12-17 ES ES15871075T patent/ES2781673T3/es active Active
- 2015-12-17 JP JP2017533220A patent/JP6649953B2/ja not_active Expired - Fee Related
- 2015-12-17 DK DK15871075.6T patent/DK3233104T3/da active
- 2015-12-17 EP EP15871075.6A patent/EP3233104B1/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Butowski et al. | A phase II clinical trial of poly-ICLC with radiation for adult patients with newly diagnosed supratentorial glioblastoma: a North American Brain Tumor Consortium (NABTC01-05) | |
| JP2016530323A5 (enExample) | ||
| RU2016148645A (ru) | Антитела к в7-н1 и к ctlа-4 для лечения немелкоклеточного рака легкого | |
| RU2018105985A (ru) | Новый подход к лечению рака с применением иммуномодуляции | |
| Sayour et al. | Manipulation of innate and adaptive immunity through cancer vaccines | |
| Brunsvig et al. | Long-term outcomes of a phase I study with UV1, a second generation telomerase based vaccine, in patients with advanced non-small cell lung cancer | |
| JP2019504892A5 (enExample) | ||
| IL292193B2 (en) | Anti-b7-h1 antibodies for treating tumors | |
| JPWO2020249693A5 (enExample) | ||
| JP2017506662A5 (enExample) | ||
| CN108392633A (zh) | Pcsk9抑制剂在恶性肿瘤免疫治疗中的应用 | |
| JP7780444B2 (ja) | ＩＦＮ－γの抗腫瘍補助薬の調製への応用 | |
| FI3463345T3 (fi) | Farmaseuttisia yhdistelmiä | |
| CN106540256A (zh) | 环二核苷酸-脂质体偶联单克隆抗体在抗肿瘤中的应用 | |
| WO2015131176A1 (en) | Compositions, methods, and kits for treatment of cancer | |
| JP2018501247A5 (enExample) | ||
| Li et al. | Boosting CAR-T cell therapy through vaccine synergy | |
| US20160340650A1 (en) | Blood derived immune stimulatory compositions | |
| CN111249272A (zh) | 茶多酚在作为免疫检查点抑制剂及制备用于抗肿瘤的药物中的应用 | |
| EP3371210B1 (en) | Combination therapy for malignant diseases | |
| CN113368217B (zh) | IFN-γ在制备抗肿瘤辅助药物中的应用 | |
| Liu et al. | Cancer biotherapy: review and prospect | |
| JP2021504329A5 (enExample) | ||
| CN109674788B (zh) | 羧胺三唑与ido1抑制剂组合在抗肿瘤中的用途 | |
| Young et al. | Ideal timing of immunotherapy with radiation in murine tumor models |